Microban and Cleanwaste Medical Unveil the new Sani-Bag+ with Built-in Antimicrobial Technology

Microban International is pleased to unveil a new partnership with Cleanwaste Medical to develop the Sani-Bag+ with built-in Microban® antimicrobial product protection. This industry-leading antimicrobial technology helps to protect the commode and bedpan liners from the growth of odor-causing bacteria, and complements Cleanwaste Medical’s proprietary formulation of deodorizing technology and NASA-developed absorbent gel polymer to create waste management solutions that are cleaner and more discreet.

The Sani-Bag+ has been meticulously designed and engineered with Microban technology to address the pressing need for clean and user-friendly disposable commode and bedpan liners in healthcare settings. The addition of innovative Microban® antimicrobial technology sets a new industry standard, further elevating the functionality of these bags to provide a fresher, more comfortable and more dignified experience for the user.

Michael Ruby, President at Microban International, commented:

“Microban is extremely proud of its partnership with Cleanwaste Medical, which brings together the expertise of both companies to deliver a practical and reliable solution for clean waste management. With over 30 years of industry leading experience, Microban’s antimicrobial technologies enhance the cleanliness of these liners by helping to prevent the growth of bacteria, ensuring fresher, cleaner and more convenient solutions for consumers and professionals.”

Sam Alhmad, National Sales Manager at Cleanwaste Medical added:

“We are very excited to partner with a trusted company of Microban’s caliber, and develop a line of antimicrobial Sani-Bag+ products that truly fulfill an unmet need, setting us apart from our competitors. These bags have been carefully designed to deliver a solution with enhanced antimicrobial performance that revolutionizes the user experience and is easily disposed of to prevent contact with waste. Microban® antimicrobial product protection is the perfect addition to these products, marrying up with our proprietary odor-neutralizing and waste absorbance technologies to make these liners the go-to choice for healthcare settings.”

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.